Deal Tracker · Regions

GCC pharma partnerships

19 partnership / collaboration deals in the GCC tracked by EPT (2024–2026). Most active: Arcera Life Sciences, Emirates Drug Establishment, ADCAN Pharma & Department of Health – Abu Dhabi. Latest: Emirates Drug Establishment → Viatris (Partnership / Collaboration, 11 Nov 2026).

19
deals tracked
16
announced in 2026
$20m
disclosed value (1 deal)
100%
partnerships, the top deal type
  • EPT has tracked 19 GCC pharma partnerships (2024–2026), 16 of them announced in 2026.
  • The countries that appear most often are UAE (12), Saudi Arabia (4), Oman (3) & Germany (2).
  • Values were disclosed for 1 of 19 deals, totalling $20m; the largest is IMGSA → Omani Investment ($20m, 3 Nov 2025).
  • The most active companies: Arcera Life Sciences (3), Emirates Drug Establishment (3), ADCAN Pharma (2) & Department of Health – Abu Dhabi (2).

Countries involved

UAE (12) · Saudi Arabia (4) · Oman (3) · Germany (2) · Switzerland (2) · Algeria (1)

Largest disclosed deals

Questions

How many GCC pharma partnerships has EPT tracked?
19 as of 11 Nov 2026, covering 2024–2026; 16 were announced in 2026. The most recent is Emirates Drug Establishment → Viatris (Partnership / Collaboration, 11 Nov 2026).
Which companies are most active in GCC pharma partnerships?
Arcera Life Sciences (3 deals), Emirates Drug Establishment (3 deals), ADCAN Pharma (2 deals), Department of Health – Abu Dhabi (2 deals), M42 (2 deals).
What is the largest disclosed GCC pharma partnership?
IMGSA → Omani Investment: $20m (Partnership / Collaboration, 3 Nov 2025). Values are as announced by the parties.
Which countries appear most in GCC pharma partnerships?
UAE (12), Saudi Arabia (4), Oman (3), Germany (2), Switzerland (2), Algeria (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)